| Indicators | AUC | 95% CI | Cutoff | Sensitivity | Specificity | PPV | NPV | p | 
|---|---|---|---|---|---|---|---|---|
| t-PSA | 0.668 | 0.606–0.730 | 14.115 | 0.641 | 0.691 | 52.23% | 78.50% | <0.000 | 
| PSAD | 0.765 | 0.711–0.819 | 0.400 | 0.563 | 0.856 | 67.29% | 78.19% | <0.000 | 
| PIRADS score | 0.864 | 0.827–0.901 | 3 | 0.844 | 0.794 | 48.65% | 92.81% | <0.000 | 
| T2WI score | 0.848 | 0.809–0.887 | 3 | 0.789 | 0.790 | 46.87% | 93.41% | <0.000 | 
| DWI score | 0.859 | 0.821–0.897 | 2 | 0.828 | 0.778 | 42.67% | 100.00% | <0.000 | 
| Total score | 0.903 | 0.872–0.933 | 6 | 0.805 | 0.864 | 62.60% | 93.05% | <0.000 | 
| Model 1 | 0.910 | 0.881–0.939 | 0.381 | 0.867 | 0.790 | 68.10% | 91.83% | <0.000 | 
| Model 2 | 0.931 | 0.906–0.956 | 0.391 | 0.883 | 0.844 | 74.83% | 93.18% | <0.000 | 
tPSA, total PSA; PSAD, PSA density; PI-RADS score, prostate imaging reporting and date system score; T2WI score, T2WI score referring to PI-RADS v2; DWI score, DWI score referring to PI-RADS score; csPCa, clinical significant prostate cancer; Total score, T2WI score + DWI score. Model 1 = f/tPSA + PSAD + T2WI score. Model 2 = f/tPSA + PSAD + Total score; AUC, area under the curve; 95% CI, 95% confidence interval for AUC; Cutoff, best cutoff; PPV, positive predictive value; NPV, negative predictive value.